Polypid Ltd. Stock Price, News & Analysis

PolyPid Ltd. (PYPD) announced significant recruitment progress in its Phase 3 SHIELD I trial for D-PLEX100, with over 300 patients enrolled. The FDA indicated that a single Phase 3 study might suffice for D-PLEX100's approval in colorectal surgery. Additionally, PolyPid has chosen brain tumors as the initial target for its OncoPLEX therapy. Financially, R&D expenses rose to $7.4 million in Q2 2021, while net losses decreased to $10.5 million compared to $19.1 million in 2020. The company maintains a cash position of $52.9 million, projected to sustain operations into late 2022.

PolyPid Ltd. (Nasdaq: PYPD), a biopharma company focused on improving surgical outcomes with advanced therapeutics, announced that Dikla Czaczkes Akselbrad, Executive Vice President and CFO, will present at the Investor Summit Virtual Conference on August 18, 2021, at 9:30 am ET. The event is scheduled from August 17-18, 2021, with opportunities for one-on-one meetings throughout. PolyPid's lead product candidate, D-PLEX100, is currently in Phase 3 clinical trials aimed at preventing surgical site infections.

PolyPid Ltd. (Nasdaq: PYPD) announced its second quarter 2021 financial results will be reported before the U.S. markets open on August 11, 2021. The company will hold a conference call at 8:30 AM Eastern Time to discuss these results and operational updates. PolyPid specializes in locally administered therapeutics aimed at improving surgical outcomes, with its lead candidate D-PLEX100 currently in Phase 3 trials to prevent surgical site infections. The company emphasizes its proprietary PLEX technology for effective drug delivery.

PolyPid Ltd. (Nasdaq: PYPD) has appointed renowned colorectal surgeon Dr. Anthony J. Senagore as its Senior Medical Director. Dr. Senagore will lead the development of PolyPid’s medical infrastructure in the U.S. and play a pivotal role in the NDA submission for D-PLEX₁₀₀, aimed at preventing surgical site infections (SSIs). His extensive experience in surgery and healthcare economics is expected to enhance the company’s mission to improve surgical outcomes. The D-PLEX₁₀₀ candidate is currently in Phase 3 clinical trials.

PolyPid (Nasdaq: PYPD) announced a presentation by CFO Dikla Czaczkes Akselbrad at The Raymond James Human Health Innovation Conference on June 23, 2021, at 9:20 am EDT. The conference aims to highlight innovations in healthcare, with PolyPid focusing on improving surgical outcomes through its proprietary PLEX technology, which enhances drug delivery. The lead candidate, D-PLEX100, is undergoing Phase 3 trials for preventing surgical site infections. The presentation will be available on the company’s Investor Relations site for 90 days following.

PolyPid Ltd. (Nasdaq: PYPD) is a biopharma company focused on enhancing surgical outcomes with controlled, extended-release therapeutics. On June 2, 2021, the company announced its executive team will present at three upcoming healthcare investor conferences: the LD Micro Invitational XI on June 10, the JMP Securities Life Sciences Conference on June 16, and the Raymond James Human Health Innovation Conference on June 21. The Raymond James presentation will be webcast live and available for 90 days on PolyPid's Investor Relations website.

PolyPid Ltd. (PYPD) announced FDA approval for a single pivotal Phase 3 study of D-PLEX100 for preventing surgical site infections (SSIs) in colorectal surgery. This decision is based on the adequate results expected from the SHIELD I trial, which has already enrolled over 200 patients. The trial aims to include a total of 616 to 900 participants across multiple centers and is set to deliver top-line results by year-end 2021. This breakthrough designation could expedite development and reduce costs significantly, addressing a major healthcare issue costing up to $10 billion annually.

PolyPid Ltd. (Nasdaq: PYPD) announced significant recruitment progress in its Phase 3 SHIELD I trial of D-PLEX100, with nearly 200 patients enrolled, a doubled recruitment rate in the last three weeks. The manufacturing facility is fully equipped to meet the first 30 months of commercial demand for D-PLEX100. Financial results reveal a net loss of $8.7 million for Q1 2021, an increase from $5.9 million in Q1 2020. Cash reserves stand at $61.4 million, expected to sustain operations into 2022. Top-line results for SHIELD I are anticipated by year-end 2021.

PolyPid Ltd. (Nasdaq: PYPD) announced it will release its first quarter 2021 financial results on May 12, 2021, before the U.S. market opens. A conference call is scheduled for 8:30 AM ET to discuss the results and business updates. PolyPid is focused on enhancing surgical outcomes through its patented PLEX technology, which offers controlled drug delivery over extended periods. Their lead candidate, D-PLEX100, is currently undergoing Phase 3 trials targeting surgical site infections.